Published on 09/12/2025

Documenting Chain of Custody for E&L Samples

In the pharmaceutical industry, ensuring the safety and efficacy of products is a paramount concern, particularly when it comes to extractables and leachables (E&L) from packaging materials and components. In this extensive guide, we present a comprehensive step-by-step tutorial on documenting the chain of custody for E&L samples, along with essential insights into analytical evaluation thresholds (AET) and dose-based thresholds (DBT). Each step will focus on compliance with US FDA, EU GMP, and other global guidelines, ensuring that your processes are not only effective but also regulatory-compliant.

1. Understanding Extractables and Leachables

Extractables and leachables are chemical substances that may migrate from packaging materials into pharmaceutical products, posing potential risks to drug safety. Extractables refer to substances that can be liberally extracted under extreme conditions, while leachables are the substances that migrate into the product under normal usage conditions. It is essential to conduct E&L assessments, especially for drug products packaged in single-use systems.

In accordance with the USP and the FDA, the evaluation of E&L involves several critical components:

• Identification of extractables from packaging components
• Assessment of leachables in the final dosage form
• Risk management to ensure patient safety

Understanding the significance of E&L while adhering to guidelines such as EU GMP Annex 1 and the PQRI guideline can substantially improve compliance and product safety.

2. Step-by-Step Protocol for Documenting Chain of Custody

Step 1: Establishing a Chain of Custody Framework

The first step is establishing a robust chain of custody (CoC) framework that details every individual involved in the sample handling process—from sample collection to analysis. Define roles and responsibilities clearly, ensuring that each person understands their obligations within the CoC.

• Designate sample collectors who are trained and authorized.
• Develop a sample tracking system to monitor every movement of the samples.
• Create a CoC form that records the date, time, collector’s name, and purpose of each transfer.

Step 2: Sample Collection Procedures

Implement standardized sampling procedures that align with both USP recommendations and FDA guidance. The samples must be collected, handled, and transported in a manner that prevents contamination or alteration.

• Choose appropriate containers that are inert and do not contribute additional extractables.
• Use sterile techniques to collect the samples, minimizing the risk of contamination.
• Document every collection event meticulously in your CoC form, including environmental conditions at the time of sampling.

Step 3: Sample Transportation

Transportation of E&L samples must be managed to uphold their integrity. Establish temperature-controlled shipping practices where necessary and utilize tracking methods such as barcoding or RFID tagging.

• Ensure that vehicles and equipment used for transportation are validated for cleanliness and suitability.
• Record the chain of possession in transit, ensuring that all personnel involved in transportation are documented.

Step 4: Sample Storage

Once received at the laboratory, samples need to be stored appropriately to maintain their integrity until analysis. Validation of storage conditions is critical, which includes the following:

• Temperature control to avoid degradation or transformation of constituents.
• Documentation of storage conditions, including any changes that occur.
• Access control to ensure that only authorized personnel can handle the samples.

Step 5: Sample Analysis and Documentation

During the analysis phase, strict adherence to the E&L testing protocols as per USP guidelines and manufacturer recommendations is crucial. Document all analytical procedures, results, and deviations:

• Utilize validated analytical methods that are fit for purpose.
• Maintain clear records of the analysis results, including any observations during the testing.
• Summarize results in final reports which reference the original CoC documentation.

3. Implementing Analytical Evaluation Thresholds (AET)

The Analytical Evaluation Threshold (AET) is a crucial component in evaluating potential leachables. The AET helps determine acceptable limits of leachables in pharmaceutical products. This section will provide in-depth guidance on AET determination, including the following steps:

Step 1: Understanding the AET Definition

The AET is defined as the threshold below which a leachable does not require identification or quantification during testing. The primary objective is to ensure patient safety while avoiding excessive testing. This approach is supported by the FDA’s process validation guidelines and relevant international standards.

Step 2: Calculating the AET

The calculation of the AET relies on understanding both the dose-based threshold (DBT) and the clinical exposure:

• For pharmaceuticals, the AET can be determined based on the maximum daily dose of the drug. A common formula involves identifying specific concentration levels of leachables that protect patient safety while maintaining statistical validity.
• It is also essential to document and justify the parameters used in AET calculations in order to meet regulatory scrutiny.

Step 3: Reviewing AET Results

Upon calculation, a comparison should be made against identified leachable profiles. Any sample exceeding the AET requires further detailed investigation and reporting. Consider the following:

• Prepare a summary document that includes AET methodology, results, and any subsequent actions.
• Maintain the integrity and security of this document to ensure it is readily available for audits or inspections by regulatory bodies such as the EMA.

4. Addressing Container Closure Integrity (CCI)

In conjunction with documenting the chain of custody and conducting E&L assessments, ensuring container closure integrity (CCI) is fundamental for the efficacy and safety of pharmaceutical products. Adequate CCI testing helps ascertain that no contaminants can enter the product, which is especially critical for sterilized products.

Step 1: CCI Testing Procedures

Establish CCI testing procedures tailored to your product’s packaging and include methods such as:

• Visual inspection and sensory evaluation.
• Robotic or manual leak-testing systems.
• Vacuum decay or pressure decay systems.

Step 2: Documenting CCI Results

Document all findings related to CCI test results in a consistent and thorough manner:

• Record environmental conditions during testing.
• Keep detailed logs of equipment calibration and maintenance.
• Summarize CCI results in the context of E&L assessments for comprehensive reports.

5. Case Studies and Real-World Applications

To further illustrate the practical aspects of documenting chain of custody for E&L samples, the following case studies demonstrate successful implementation in real-world scenarios. These instances highlight the importance of stringent adherence to best practices in E&L management.

Case Study 1: Single-Use Systems Validation

A global biopharmaceutical company utilized robust chain of custody documentation for their single-use systems. By employing a comprehensive CoC framework, they successfully navigated an inspection by the MHRA. The meticulous documentation highlighted their adherence to all regulatory requirements, leading to swift approval of their product line.

Case Study 2: Analytical Evaluation Thresholds

Another pharmaceutical firm executed a systematic approach to determine AET for a new injectable drug. Through precise documentation and calculations based on patient exposure estimates, they were able to establish acceptable limits for leachables, showcasing a strong alignment with both FDA and global standards.

6. Key Takeaways and Final Considerations

In conclusion, documenting the chain of custody for extractables and leachables samples is essential for compliance with cGMP and regulatory guidelines. By following these structured steps, pharmaceutical professionals can ensure not only patient safety but also maintain the integrity of their products throughout their lifecycle.

Key Takeaways:

• Establish a robust CoC framework with clearly defined roles.
• Document every step of sample handling meticulously to withstand regulatory scrutiny.
• Conduct AET calculations with justifiable parameters while adhering to best practices.
• Regularly test and document CCI results to ensure containment integrity.

By implementing these strategies, organizations can improve their E&L practices and optimize their readiness for audits by bodies such as the FDA, EMA, and other regulatory authorities.